MY129741A - Crystalline form of telmisartan sodium - Google Patents

Crystalline form of telmisartan sodium

Info

Publication number
MY129741A
MY129741A MYPI20024051A MYPI20024051A MY129741A MY 129741 A MY129741 A MY 129741A MY PI20024051 A MYPI20024051 A MY PI20024051A MY PI20024051 A MYPI20024051 A MY PI20024051A MY 129741 A MY129741 A MY 129741A
Authority
MY
Malaysia
Prior art keywords
crystalline form
telmisartan sodium
telmisartan
preparing
sodium
Prior art date
Application number
MYPI20024051A
Inventor
Kai Dr Donsbach
Irmgard Hof
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY129741(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY129741A publication Critical patent/MY129741A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

THE INVENTION RELATES TO A CRYSTALLINE SODIUM SALT OF 4'-[2-N-PROPYL-4-METHYL-6-(1-METHYLBENZIMIDAZOL-2-YL) BENZIMIDAZOL-1-YLMETHYL]BIPHENYL-2-CARBOXYLIC ACID (INN:TELMISARTAN), PROCESSES FOR PREPARING IT AND THE USE THEREOF FOR PREPARING A PHARMACEUTICAL COMPOSITION.
MYPI20024051A 2001-10-31 2002-10-29 Crystalline form of telmisartan sodium MY129741A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (en) 2001-10-31 2001-10-31 Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament

Publications (1)

Publication Number Publication Date
MY129741A true MY129741A (en) 2007-04-30

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20024051A MY129741A (en) 2001-10-31 2002-10-29 Crystalline form of telmisartan sodium

Country Status (34)

Country Link
EP (1) EP1442023B1 (en)
JP (1) JP5124076B2 (en)
KR (1) KR100929502B1 (en)
CN (1) CN100509789C (en)
AR (1) AR037148A1 (en)
AT (1) ATE370125T1 (en)
AU (1) AU2002338886B2 (en)
BR (1) BR0213568A (en)
CA (1) CA2463146C (en)
CO (1) CO5580785A2 (en)
CY (1) CY1107504T1 (en)
DE (2) DE10153737A1 (en)
DK (1) DK1442023T3 (en)
EA (1) EA007596B1 (en)
EC (1) ECSP045089A (en)
ES (1) ES2291505T3 (en)
HR (1) HRPK20040372B4 (en)
HU (1) HUP0402391A3 (en)
IL (2) IL161165A0 (en)
ME (1) MEP43608A (en)
MX (1) MXPA04004013A (en)
MY (1) MY129741A (en)
NO (1) NO326465B1 (en)
NZ (1) NZ532716A (en)
PE (1) PE20030629A1 (en)
PL (1) PL211462B1 (en)
PT (1) PT1442023E (en)
RS (1) RS50879B (en)
SA (1) SA02230419B1 (en)
SI (1) SI1442023T1 (en)
TW (2) TWI333419B (en)
UA (1) UA82833C2 (en)
UY (1) UY27520A1 (en)
WO (1) WO2003037876A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
KR100908308B1 (en) * 2004-05-05 2009-07-17 테바 파마슈티컬 인더스트리즈 리미티드 Preparation of high purity candesartan cilexetil
EP1805146A4 (en) 2004-10-18 2009-01-14 Reddys Lab Ltd Dr Process for preparing telmisartan
WO2006050509A2 (en) * 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (en) * 2008-07-29 2010-02-10 Sandoz AG Method for processing microbiologically produced cyclic oligopeptides
EP2432452B1 (en) 2009-05-20 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical telmisartan drink solution
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
WO2012055941A1 (en) 2010-10-27 2012-05-03 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
ES2603028T3 (en) 2011-11-25 2017-02-23 Adverio Pharma Gmbh Procedure for the preparation of (Z) -alpha-fluoro-beta-amino-acrylaldehydes
UA119794C2 (en) 2014-10-21 2019-08-12 Аріад Фармасьютикалз, Інк. CRYSTAL FORM 5-CHLORO-N4- [2- (DIMETHYLPHOSPHORYL) PHENYL] -N2- {2-METHOXY-4- [4- (4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL} -DIAMINE
KR101872726B1 (en) * 2016-07-28 2018-06-29 주식회사 씨트리 Telmisartan methanesulfonate and pharmaceutical composition comprising the same
PT3648761T (en) 2017-07-07 2024-06-05 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
US20220098197A1 (en) * 2019-01-10 2022-03-31 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Salts of heterocyclic compound and use thereof
KR20220054292A (en) 2019-07-09 2022-05-02 베링거잉겔하임베트메디카게엠베하 Telmisartan for the treatment of high blood pressure in dogs
US20240390317A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
KR20260019532A (en) 2023-05-24 2026-02-10 베링거잉겔하임베트메디카게엠베하 Combination treatment and/or prevention of renal disease and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
TW202541793A (en) 2023-12-15 2025-11-01 德商百靈佳殷格翰維美迪加股份有限公司 Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591762A (en) * 1991-02-06 1997-01-07 Dr. Karl Thomae Gmbh Benzimidazoles useful as angiotensin-11 antagonists
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
DK0883401T3 (en) * 1996-02-29 2003-05-05 Novartis Ag AT1 receptor antagonist to stimulate apoptosis
DE19901921C2 (en) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament

Also Published As

Publication number Publication date
PL211462B1 (en) 2012-05-31
SI1442023T1 (en) 2007-12-31
HRP20040372A8 (en) 2025-09-12
CA2463146A1 (en) 2003-05-08
DE50210719D1 (en) 2007-09-27
ATE370125T1 (en) 2007-09-15
ECSP045089A (en) 2004-06-28
AR037148A1 (en) 2004-10-27
WO2003037876A1 (en) 2003-05-08
SA02230419B1 (en) 2007-07-31
PT1442023E (en) 2007-09-17
NZ532716A (en) 2007-06-29
CY1107504T1 (en) 2013-03-13
TWI341200B (en) 2011-05-01
HUP0402391A3 (en) 2010-03-29
MEP43608A (en) 2011-02-10
CO5580785A2 (en) 2005-11-30
NO20041758L (en) 2004-04-29
CN1578772A (en) 2005-02-09
TW200300082A (en) 2003-05-16
JP2005536445A (en) 2005-12-02
IL161165A0 (en) 2004-08-31
DK1442023T3 (en) 2007-11-05
DE10153737A1 (en) 2003-05-28
MXPA04004013A (en) 2004-06-18
PE20030629A1 (en) 2003-07-14
KR20050035172A (en) 2005-04-15
HRPK20040372B4 (en) 2025-09-12
HK1073841A1 (en) 2005-10-21
UY27520A1 (en) 2003-05-30
TW201034664A (en) 2010-10-01
KR100929502B1 (en) 2009-12-03
EP1442023A1 (en) 2004-08-04
CA2463146C (en) 2011-01-25
YU36304A (en) 2006-08-17
JP5124076B2 (en) 2013-01-23
AU2002338886B2 (en) 2008-04-17
ES2291505T3 (en) 2008-03-01
HUP0402391A2 (en) 2005-03-29
TWI333419B (en) 2010-11-21
HRP20040372A2 (en) 2004-10-31
HRPK20040372B3 (en) 2006-02-28
NO326465B1 (en) 2008-12-08
RS50879B (en) 2010-08-31
PL367477A1 (en) 2005-02-21
EP1442023B1 (en) 2007-08-15
EA007596B1 (en) 2006-12-29
IL161165A (en) 2009-12-24
UA82833C2 (en) 2008-05-26
BR0213568A (en) 2004-09-08
EA200400479A1 (en) 2004-10-28
CN100509789C (en) 2009-07-08

Similar Documents

Publication Publication Date Title
MY129741A (en) Crystalline form of telmisartan sodium
TW200509914A (en) Pharmaceutical formulation of the telmisartan sodium salt
MY122755A (en) Polymorphs of telmisartan
GEP20064005B (en) Use of novel benzoimidazole derivatives as antiproliferative agents
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
MXPA04001037A (en) N-phenylpyrrole guanidine derivatives as melanocortin reception ligands.
MXPA02003977A (en) INHIBITORS OF agr;L.
BR0200782A (en) Compounds for the treatment of ischemia
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
PT1664016E (en) Therapeutic agents useful for treating pain
WO2002058692A3 (en) Halogenated composition, method for preparing same and uses thereof
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
MXPA05006889A (en) Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents.
MX2010003594A (en) Crystalline forms of dmxaa sodium salt.
GB0212410D0 (en) Organic compounds
TR200101388T2 (en) New pyrimidine derivatives and processes for preparing them
GB0103046D0 (en) Organic Compounds
MY160963A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
BRPI0513549A (en) pharmaceutical compositions for the treatment of leishmaniasis
IL179813A0 (en) S-tenatoprazole sodium monohydrate salt and use thereof in the form of a proton pump inhibitor
AU2003216965A1 (en) Compounds, particularly of urea derivatives or ester derivatives of haloacetamidobenzoic acid and use thereof for the treatment of parasitic diseases